Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study by unknown
RESEARCH ARTICLE Open Access
Higher plasma levels of
lysophosphatidylcholine 18:0 are related
to a lower risk of common cancers in a
prospective metabolomics study
Tilman Kühn1*, Anna Floegel2, Disorn Sookthai1, Theron Johnson1, Ulrike Rolle-Kampczyk3, Wolfgang Otto4,
Martin von Bergen3,4,5, Heiner Boeing2 and Rudolf Kaaks1
Abstract
Background: First metabolomics studies have indicated that metabolic fingerprints from accessible tissues might
be useful to better understand the etiological links between metabolism and cancer. However, there is still a lack
of prospective metabolomics studies on pre-diagnostic metabolic alterations and cancer risk.
Methods: Associations between pre-diagnostic levels of 120 circulating metabolites (acylcarnitines, amino acids,
biogenic amines, phosphatidylcholines, sphingolipids, and hexoses) and the risks of breast, prostate, and colorectal
cancer were evaluated by Cox regression analyses using data of a prospective case-cohort study including 835
incident cancer cases.
Results: The median follow-up duration was 8.3 years among non-cases and 6.5 years among incident cases of
cancer. Higher levels of lysophosphatidylcholines (lysoPCs), and especially lysoPC a C18:0, were consistently related
to lower risks of breast, prostate, and colorectal cancer, independent of background factors. In contrast, higher
levels of phosphatidylcholine PC ae C30:0 were associated with increased cancer risk. There was no heterogeneity
in the observed associations by lag time between blood draw and cancer diagnosis.
Conclusion: Changes in blood lipid composition precede the diagnosis of common malignancies by several years.
Considering the consistency of the present results across three cancer types the observed alterations point to a
global metabolic shift in phosphatidylcholine metabolism that may drive tumorigenesis.
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Background
The simultaneous measurement of a large variety of
small molecules in accessible tissues by metabolomics
techniques may facilitate the identification of metabolic
fingerprints of different cancers [1]. First prospective
metabolomics studies have shown that elevations in cir-
culating branched-chained amino acids 2–5 years prior
to diagnosis are related to increased risk of pancreatic
adenocarcinoma [2], that significant differences in serum
levels of phosphatidylcholines and fatty acids between
later prostate cancer cases and controls can be detected
[3], and that pre-diagnostic serum concentrations of gly-
cochenodeoxycholate are associated with colon cancer
risk [4]. A complex pattern of pre-diagnostic metabolites
representing several pathways has been identified in an-
other prospective study on hepatocellular carcinoma [5].
For other cancers, differences in plasma metabolite con-
centrations between cases and controls have also been
demonstrated, but prospective data are missing [1].
Here, we report results of the largest prospective
metabolomics study so far on cancers of the breast,
colorectum, and prostate. Our goal was the identification
of metabolites that may give insight into metabolic al-
terations preceding the manifestation of cancer. In a
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case-cohort subset of the prospective population-based
EPIC-Heidelberg study, we analyzed pre-diagnostic levels
of 120 plasma metabolites by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) and flow injec-
tion analysis-tandem mass spectrometry (FIA-MS/MS),
and evaluated associations between these metabolites and
cancer risk over time.
Methods
Study population
EPIC-Heidelberg was established as part of the European
Prospective Investigation into Cancer and Nutrition (EPIC)
between 1994 and 1998 [6]. Overall, 25,540 adults (53.3 %
females) aged 35–65 years from the local general popula-
tion entered the study [7]. The vast majority of participants
are white. Detailed information on habitual diet, smoking,
alcohol consumption, physical activity, and socio-economic
status was obtained by questionnaires and during inter-
views. In addition, anthropometric measurements were
taken by trained personnel. Blood was drawn, processed,
and aliquoted into 0.5 ml straws of serum (8 straws),
plasma (12 straws), buffy coat (4 straws), and erythrocytes
(4 straws), which were stored in liquid nitrogen at −196 °C.
Plasma straws used for the present study were retrieved for
the first time, i.e. they had not undergone freeze-and-thaw
cycles.
Since the baseline, participants are followed-up by active
and passive procedures [8]. Self-reported and registry-
derived incident cases of cancer were validated by study
physicians who accessed diagnostic records provided by
treating physicians and hospitals. A case-cohort design [9]
was chosen for the present metabolomics study and metab-
olites were measured in pre-diagnostic blood samples of
cancer cases and a random subcohort [10]. Individuals in
the case-cohort selection were free of diabetes at baseline,
as the subcohort was initially drawn for the EPIC-InterAct
study on incident diabetes [10]. All incident primary cases
of breast (ICD-10 C50), prostate (ICD-10 C61), and colo-
rectal cancer (ICD-10 C18–20) as well as cases secondary
to non-melanoma skin cancer that had occurred before 31
December 2006 were selected. After exclusion of partici-
pants with missing covariate information (n = 4) and preva-
lent cancer cases (n = 65), the subcohort comprised 774
individuals. The final numbers of incident cases of breast,
prostate, and colorectal cancer were 362, 310, and 163,
respectively, after exclusions due to missing covariate
information (breast cancer: n = 3; colorectal cancer: n = 2).
Ethics
The present study was approved by the Ethics Committee
of the Medical Faculty of the University of Heidelberg
(Heidelberg, Germany). The study participants pro-
vided written consent for the use of their blood samples
and data.
Laboratory analyses
Metabolites, i.e. 40 acylcarnitines, 21 amino acids, 14
biogenic amines and creatinine, 76 phosphatidylcholines
(PCs), 14 lysophosphatidylcholines (lysoPCs), 15 sphin-
gomyelins, and overall hexose were quantified using the
MetaDisIDQ™ Kit (Biocrates, Innsbruck, Austria). Sample
preparation and measurements were carried out according
to the suppliers’ protocol and have been described in detail
elsewhere [11]. In short, 10 μl of standards, quality con-
trols, and plasma samples, which had been thawed for
30 minutes at −4 °C, were pipetted onto filter paper within
each well of the 96-well plate that had been commercially
prepared. Nitrogen gas was used to dry the samples
followed by application of phenylisothiocyanate (PITC)
and extraction of metabolites from the filter paper. The
eluate was then dried under flowing nitrogen gas and the
wells sealed. Kit plates were shipped to the partner labora-
tory at the Department of Proteomics, Helmholtz Centre
for Environmental Research (Leipzig, Germany), where li-
quid FIA-MS/MS (amino acids and biogenic amines) and
LC-MS/MS (lipids and hexoses) analyses were carried out
on each kit. Samples were blinded to the laboratory team.
Metabolites were detected using an Agilent 1100 HPLC
(Agilent Technologies, Böblingen, Germany) coupled to
an API 5000 triple quadrupole mass spectrometer (AB
Sciex, Darmstadt, Germany).
The MetaDisIDQ™ software (Biocrates) was used to
randomize samples of the study population so that
samples of cases and non-cases were stratified within and
across batches. Each analytical batch contained three qual-
ity control (QC) samples of lyophilized human EDTA-
plasma with standardized low, medium (spiked), and high
(spiked) concentrations of internal standards to monitor
the validity of measurements. Two blinded pooled QC
plasma samples were included in duplicate to independ-
ently verify the consistency of measurements within and
across batches. In addition to a commercially available
pooled QC sample (NIST SRM 1950), we used a pooled
sample from our own population. One blank without in-
ternal standard was included on each batch to calculate
background levels and to check the system for contamin-
ation. Three additional zero samples with internal stan-
dards, but no analytes were integrated to calculate limits
of detection.
Data pre-processing and statistical analyses
Metabolites with more than 25 % missing values (n = 2),
within batch coefficients of variation greater than 25 %
(n = 12), or more than 25 % of values below the limit
of detection (n = 47) were excluded so that 120 out of
181 metabolites were used for statistical evaluation
(Additional file 1). All metabolite values were then
log2-tranformed and normalized by metabolite-wise
batch-standardization [12]. Multivariable outliers were
Kühn et al. BMC Medicine  (2016) 14:13 Page 2 of 9
identified by robust principal components analyses and
excluded [13]. Spearman’s rho adjusted for age and sex
was calculated to detect correlations between metabolites.
Associations between metabolite concentrations and
epidemiological covariates were assessed by calculating
Spearman’s correlations (continuous covariates) and
geometric mean values across categories (categorical
covariates). Cox proportional hazards regression analyses
were carried out to evaluate the relationships between cir-
culating metabolites and cancer risks. Metabolite concen-
trations were divided into quartiles and linear trends were
tested for using log2-transformed metabolite values on the
continuous scale. The so-called Prentice method was used
to account for the case-cohort design of the study [14].
Age was used as the underlying timescale, with age at
recruitment as age at entry and age at the end of follow-
up, death, or cancer diagnosis, whichever came first, as
age at exit. The proportional hazards assumption was
tested based on Schoenfeld residuals [15]. With respect to
the vast majority of metabolites, and particularly those
which showed significant associations with cancer risk, no
strong violations of the proportional hazards assumption
were noted. Adjustment factors for multivariable Cox re-
gression models were selected based on literature review.
The Bonferroni method was used to adjust for multiple
testing, i.e. P values of single tests were divided by the total
number of tests (n = 120). All statistical tests were two-
sided and P values below 0.05 were considered statistically
significant. All analyses were performed using SAS 9.3
(SAS Institute, Cary, NC, USA).
Table 1 Characteristics of the study population (EPIC-Heidelberg, case-cohort sample)
Incident cancer cases Subcohort
Colorectum Breast Prostate Women Men
N 163 362 310 426 348
Age at recruitment (years) 55.8 ± 6.4 51.4 ± 7.8 57.9 ± 5.2 49.1 ± 8.5 52.3 ± 7.1




BMI (kg/m2) 27.2 ± 3.8 25.1 ± 4.4 26.9 ± 3.3 24.8 ± 4.4 26.5 ± 3.4
Waist circumference (cm) 93.5 ± 12.5 81.0 ± 11.3 96.2 ± 9.6 79.8 ± 11.0 95.2 ± 9.8
Smoking (%)
Never 31.9 55.0 42.6 50.5 34.4
Former 44.8 25.7 41.6 28.4 41.7
Current 23.3 19.3 15.8 21.1 23.9
Physical activity (%)a
Inactive 12.3 11.6 11.6 9.9 11.8
Moderately inactive 34.3 35.1 36.1 34.5 31.3
Moderately active 27.0 26.5 29.7 29.8 29.6
Active 26.4 26.8 22.6 25.8 27.3
Education level (%)
Primary school 33.1 24.6 34.2 25.6 25.9
Secondary school 34.4 48.6 32.9 51.2 33.0
University degree 32.5 26.8 32.9 23.2 41.1
NSAID use (%) 9.2 2.5 8.7 2.1 6.0
Age at diagnosis (years) 62.3 ± 7.2 57.5 ± 7.8 64.5 ± 5.2
Stage at diagnosis (%)
Local 40.5 62.2 70.7
Regional 40.5 32.0 24.8
Distant 19.0 2.2 3.2
Unknown - 3.6 1.3
Values are means ± standard deviations or proportions. aAccording to the Cambridge physical activity index
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Fig. 1 (See legend on next page.)
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Results
Characteristics of the study population are shown in
Table 1. The case-cohort sample comprised a random
subcohort (n = 774) and cases of breast (n = 362), prostate
(n = 310), and colorectal cancer (n = 163). Median follow-
up durations were 8.34 years in the subcohort and
6.36 years (breast cancer), 6.57 years (colorectal cancer),
6.83 years (prostate cancer), and 6.48 (overall cancer)
among incident cases.
Associations between metabolite levels and cancer risk
are depicted in Fig. 1. The strongest statistical relation-
ship was found between levels of the lysoPC a C18:0 and
(See figure on previous page.)
Fig. 1 Plasma metabolite concentrations and cancer risk. P values from Cox regression analyses on individual metabolite concentrations on the
log-2 scale and cancer risk are represented by the needles. The blue dashed lines depict the significance threshold at an uncorrected P <0.05 and
green dashed lines depict the significance threshold after Bonferroni correction (0.05 divided by 120). Unfilled circles indicate inverse associations
and filled circles indicate direct associations. Metabolites are grouped by chemical properties: block 1, acylcarnitines; block 2, amino acids; block 3,
biogenic amines; block 4, lysophosphatidylcholines (lysoPCs); block 5, diacylphosphatidylcholines; block 6, acyl-alkyl-phosphatidylcholines; block 7,
sphingolipids; and block 8, overall hexoses. All multivariable Cox regression models were adjusted for age, smoking (never, former, current),
lifetime alcohol intake (g/d), current aspirin use (yes/no), physical activity (Cambridge index), waist circumference (cm), BMI (continuous),
height (cm), and education level (primary school, secondary school, university degree). Analyses on breast cancer risk were additionally adjusted for
menopausal status, current HRT use (yes/no), current oral contraceptive use (yes/no), and at least one full term pregnancy (yes/no). Analyses
on colorectal cancer risk were additionally adjusted for sex, fiber intake (g/d), and processed meat intake (g/d)
Table 2 Hazard ratios (95 % CIs) of cancer across quartiles of lysoPC a C18:0 and PC ae C30:0 concentrations
Quartile 1 Quartile 2 Quartile 3 Quartile 4 ptrend (raw) ptrend (corrected) Measured in
LysoPC a C18:0 100 %
Breast cancer Mediana 13.52 17.34 20.36 23.23
n cases 137 96 84 45
Ref. 0.63 (0.41, 0.97) 0.65 (0.41, 1.02) 0.29 (0.18, 0.47) 0.00004 0.00421
Prostate cancer Median 15.33 18.69 21.43 26.3
n cases 93 96 73 48
Ref. 1.31 (0.75, 2.28) 0.79 (0.45, 1.39) 0.57 (0.33, 0.98) 0.01388 1
Colorectal cancer Median 14.37 17.71 21.21 24.13
n cases 47 47 46 23
Ref. 1.16 (0.67, 2.01) 1.06 (0.62, 1.82) 0.50 (0.28, 0.90) 0.00196 0.2348
Overall cancer Median 14.37 17.93 20.85 24.63
n cases 280 228 211 116
Ref 0.83 (0.61, 1.12) 0.74 (0.55, 1.00) 0.37 (0.27, 0.51) 1.10 × 10−9 1.10 × 10−7
PC ae C30:0 95.6 %
Breast cancer Median 0.33 0.40 0.47 0.60
n cases 69 74 92 113
Ref. 1.08 (0.67, 1.75) 1.45 (0.88, 2.37) 1.97 (1.20, 3.23) 0.00522 0.6260
Prostate cancer Median 0.28 0.35 0.4 0.53
n cases 64 63 71 100
Ref. 0.89 (0.50, 1.58) 1.38 (0.78, 2.44) 1.89 (1.06, 3.36) 0.00194 0.2328
Colorectal cancer Median 0.28 0.38 0.45 0.59
n cases 36 36 46 39
Ref 1.00 (0.54, 1.83) 1.79 (1.01, 3.18) 1.84 (1.02, 3.34) 0.01069 1
Overall cancer Median 0.30 0.37 0.44 0.58
n cases 168 174 208 253
Ref 1.03 (0.73, 1.45) 1.41 (1.01, 1.96) 1.85 (1.31, 2.60) 0.00026 0.03137
Results from Cox proportional hazards regression analyses on pre-diagnostic metabolite concentrations and cancer risk over time. All multivariable Cox models were
adjusted for age, smoking (never, former, current), lifetime alcohol intake (g/d), current aspirin use (yes/no), physical activity (Cambridge index), waist circumference (cm),
BMI (continuous), height (cm), and education level (primary school, secondary school, university degree). Analyses on breast cancer risk were additionally adjusted for
menopausal status, current HRT use (yes/no), current oral contraceptive use (yes/no), and at least one full term pregnancy (yes/no). Analyses on colorectal cancer risk
were additionally adjusted for sex, fiber intake (g/d), and processed meat intake (g/d). aMedian metabolite concentrations in μmol/L
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breast cancer risk, at a P value of 0.00421 corrected for
multiple testing by the Bonferroni method. The hazard
ratio (HR) of breast cancer among women in the highest
quartile of lysoPC a C18:0 concentrations was 0.29
(95 % CI, 0.18–0.47, Table 2). The second and third
strongest associations were between PC ae C38:1 and
breast cancer risk (HR = 0.53, 95 % CI, 0.34–0.83, P = 0.08),
and PC ae C30:0 and prostate cancer risk (HR = 1.89, 95 %
CI, 1.06–3.36, P = 0.23). Considering the consistency of as-
sociations between levels of lysoPC a C18:0 and PC ae
C30:0 and individual cancer types, visualized in Fig. 1, we
decided to expand our analyses to overall cancer risk.
LysoPC a C18:0 concentrations were strongly associated
with decreased overall cancer risk (HR = 0.37, 95 % CI,
0.27–0.51, P <0.0001, Table 2). Similarly, levels of lysoPC a
C18:1 and further lysoPCs, which positively correlated with
lysoPC a C18:0 levels (Fig. 2), showed inverse associations
(Fig. 1, Table 2). Circulating PC ae C30:0 was directly
associated with overall cancer risk (HR = 1.85, 95 % CI,
1.31–2.60, P = 0.0314, Table 2).
There was no heterogeneity in the associations be-
tween lysoPC a C18:0 or PC ae C30:0 concentrations
and cancer risk by lag time (Additional file 2: Table S2).
No meaningful associations between metabolite levels
and epidemiological covariates such as age, BMI, dietary
factors, or smoking status were observed (Tables 3 and 4).
Moderate to strong positive correlations were observed
between a majority of metabolites within chemical groups
(Fig. 2 and Additional file 2: Figure S1).
Discussion
Since the metabolite levels in our study were measured
in blood samples taken years before diagnosis, the present
associations between lysoPC and PC ae C30:0 concentra-
tions with the risk of cancer may represent general meta-
bolic alterations fostering the development and growth of
cancer cells. In contrast to the relationship between PC ae
C30:0 and cancer risk that has not been described in
the literature, our findings of associations between lysoPC
levels and cancer risk are consistent with results of three
case-control studies, in which lower blood concentrations
of lysoPCs in patients with breast, prostate and colorectal
cancer were found, as compared to controls [16-18].
While a potential shift between lysoPC levels from
blood to tumor tissue indicates a higher consumption of
lysoPCs by cancer cells, specific signaling properties of
lysoPCs in cancer remain to be established [19]. Alterna-
tively, lysoPCs may act as carriers of fatty acids, and
extracellular hydrolization of lysoPC a C18:0 and lysoPC
a C18:1, followed by a rapid uptake of the respective fatty
acids, i.e. stearic (18:0) and oleic acid (18:1), appears to be
a characteristic of solid tumors in mice [20]. This is in line
with epidemiologic observations of inverse associations
between stearic acid levels and breast [21], prostate [3],
and colorectal cancer risk [4]. However, it appears spuri-
ous why lysoPC a C16:0, lysoPC a C18:1, and lysoPC a
C20:4 concentrations also showed inverse associations
with cancer risk in our study, whereas circulating palmitic
(16:0), oleic (18:1), and arachidonic acid (20:4)—that were
not covered by our assay—were not related to cancer risk
in previous epidemiological studies.
Possibly, other degradation products of lysoPCs than fatty
acids drive tumorigenesis. Extracellular lysoPCs are
converted into lysophosphatidic acid (LPA), which in-
duces tumor growth, by autotaxin (ATX), a secreted
lysophospholipase D. Overexpression of ATX and LPA
receptors has been proposed to be a common feature of
several cancers, and both ATX and LPA receptor knockout
mice show lower cancer risk [22–24]. Moreover, lysopho-
sphatidylcholine acyltransferase 1 (LPCAT1), which con-
verts lysoPCs into PCs is overexpressed in several cancers,
and increased incorporation of PCs into cell membranes
Fig. 2 Age- and sex-adjusted Spearman’s correlations between levels
of different lysoPCs
Table 3 Age- and sex-adjusted partial Spearman’s correlations between levels of lysoPC a C18:0 as well as PC ae C30:0 and
covariates
Age BMI Height (cm) Waist (cm) Fiber intake (g/d) Meat intake (g/d)
LysoPC a C18:0 −0.01 −0.01 −0.03 −0.02 0.00051 0.06
PC ae C30:0 −0.02 −0.17 0.06 −0.16 0.03 −0.22
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may facilitate proliferation, adhesion, and motility of cancer
cells [25–27].
Less is known about the role of PC ae C30:0 in car-
cinogenesis. Elevated PC ae C30:0 concentrations were
detected in plasma of patients with ovarian endometriosis
[28]. Even though PC levels were inversely associated with
prostate cancer risk in one previous study [3] and have
been found to be higher in cancer cells than in non-
malignant cells [29–31], a distinct biological function of
PC ae C30:0 has not been described and ours was the first
prospective study on PC ae C30:0 and cancer to our
knowledge.
Levels of lysoPCs and PC ae C30:0 were not related to
background factors such as BMI, physical activity, or
smoking in our study. While PC ae C30:0 has not been
shown to be associated with chronic diseases in previous
studies, it may seem noteworthy that lysoPC a C18:2 has
been proposed to be a potential pre-diagnostic biomarker
of diabetes [32]. At the same time, associations between
lysoPC a C18:0 and diabetes risk have not been observed
in previous studies [32, 33], and potential mediation of
associations between lysoPCs and cancer risk by a pre-
diabetic state does therefore not appear to be a valid
explanation for the present findings.
A limitation of our study is that only a single blood
sample was available; however, reasonable mid-term
reliability of metabolite levels over time has been dem-
onstrated in reproducibility studies [34–37]. While we
cannot provide data on the stability of the analyzed
metabolites in long-term storage at −196 °C, it has been
shown that freeze-and-thaw cycles do not substantially
affect most metabolites covered by the kit we used
[38, 39]. Longer exposure to room temperature, which
may indeed lead to an increase of lysoPC levels [38],
was avoided in our study, and the plasma samples of
case patients and non-cases used for the present meta-
bolomics project have been stored and prepared under
exactly the same conditions. Many of the metabolites
measured in our project are not part of metabolomics
platforms previously used in other studies, which hampers
comparisons across studies and underlines the need
for standardization [1]. Undoubtedly, replication of the
present associations is needed before metabolites such as
lysoPC a C18:0 or PC ae C30:0 may eventually be used as
cancer biomarkers. Moreover, our findings require further
investigation in mechanistic studies, before more definite
conclusions on lysoPCs and PC ae C30:0 in tumorigenesis
can be drawn.
Conclusion
In summary, we observed consistent associations of lysoPC
a C18:0 and PC ae C30:0 concentrations with the risk of
three frequent cancer types independent of background fac-
tors. Intriguingly, associations in our study did not depend
on lag time between blood draw and diagnosis, indicating
that low levels of lysoPCs and high levels of PC ae C30:0
are cancer risk factors rather than early markers of disease.
The consistency of findings across three cancer types points
to global rather than cancer type-specific alterations under-
lying the observed associations. Further studies are needed
to evaluate whether the top hits from our study may have a
potential as biomarkers of cancer risk.
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